HPHo-Jin Park

Ho-Jin Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ho-Jin Park has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Bo Wang

    Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts; Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts

    3 shared publications
  • Jonas B. Galper

    Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, United States of America

    3 shared publications
  • Charles M. Welzig

    Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts; Departments of Neurology, Physiology and Biomedical Engineering, Medical College of Wisconsin, Milwaukee, Wisconsin

    2 shared publications
  • Chuang Du

    Department of Neuroscience, Tufts University School of Medicine, Boston, MA

    2 shared publications
  • Mark J. Aronovitz

    Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA

    2 shared publications
  • Yali Zhang

    Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA

    2 shared publications

Latest Publications

  • QRS/T-wave and calcium alternans in a type I diabetic mouse model for spontaneous postmyocardial infarction ventricular tachycardia: A mechanism for the antiarrhythmic effect of statins

    by Hongwei Jin, Charles M. Welzig, Mark Aronovitz, Farzad Noubary, Robert Blanton, Bo Wang, Mohammad Rajab, Alfred Albano, Mark S. Link, Sami F. Noujaim, et al.


  • Open Access

    Glycogen Synthase Kinase-3β Inhibition Ameliorates Cardiac Parasympathetic Dysfunction in Type 1 Diabetic Akita Mice

    by Yali Zhang, Charles M. Welzig, Kristen L. Picard, Chuang Du, Bo Wang, Jen Q. Pan, John M. Kyriakis, Mark J. Aronovitz, William C. Claycomb, Robert M. Blanton, et al.

    Decreased heart rate variability (HRV) is a major risk factor for sudden death and cardiovascular disease. We previously demonstrated that parasympathetic dysfunction in the heart of the Akita type 1 diabetic mouse was due to a decrease in the level of the sterol response element–binding protein (SREBP-1). Here we demonstrate that hyperactivity of glycogen synthase kinase-3β (GSK3β) in the atrium of the Akita mouse results in decreased SREBP-1, attenuation of parasympathetic modulation of heart rate, measured as a decrease in the high-frequency (HF) fraction of HRV in the presence of propranolol, and a decrease in expression of the G-protein coupled inward rectifying K+ (GIRK4) subunit of the acetylcholine (ACh)-activated inward-rectifying K+ channel (IKACh), the ion channel that mediates the heart rate response to parasympathetic stimulation. Treatment of atrial myocytes with the GSK3β inhibitor Kenpaullone increased levels of SREBP-1 and expression of GIRK4 and IKACh, whereas a dominant-active GSK3β mutant decreased SREBP-1 and GIRK4 expression. In Akita mice treated with GSK3β inhibitors Li+ and/or CHIR-99021, Li+ increased IKACh, and Li+ and CHIR-99021 both partially reversed the decrease in HF fraction while increasing GIRK4 and SREBP-1 expression. These data support the conclusion that increased GSK3β activity in the type 1 diabetic heart plays a critical role in parasympathetic dysfunction through an effect on SREBP-1, supporting GSK3β as a new therapeutic target for diabetic autonomic neuropathy.


  • Role of SREBP-1 in the Development of Parasympathetic Dysfunction in the Hearts of Type 1 Diabetic Akita Mice

    by Ho-Jin Park, Yali Zhang, Chuang Du, C. Michael Welzig, Christopher Madias, Mark J. Aronovitz, Serban P. Georgescu, Isaac Naggar, Bo Wang, Young-Bum Kim, et al.

    Rationale: Diabetic autonomic neuropathy (DAN), a major complication of diabetes mellitus, is characterized, in part, by impaired cardiac parasympathetic responsiveness. Parasympathetic stimulation of the heart involves activation of an acetylcholine-gated K + current, I KAch , via a (GIRK1) 2 /(GIRK4) 2 K + channel. Sterol regulatory element binding protein-1 (SREBP-1) is a lipid-sensitive transcription factor. Objective: We describe a unique SREBP-1–dependent mechanism for insulin regulation of cardiac parasympathetic response in a mouse model for DAN. Methods and Results: Using implantable EKG transmitters, we demonstrated that compared with wild-type, Ins2 Akita type I diabetic mice demonstrated a decrease in the negative chronotropic response to carbamylcholine characterized by a 2.4-fold decrease in the duration of bradycardia, a 52±8% decrease in atrial expression of GIRK1 ( P P KAch with a peak value of −181±31 pA/pF compared with −451±62 pA/pF ( P KAch activity in atrial myocytes from these mice to levels in wild-type mice. Insulin treatment of cultured atrial myocytes stimulated GIRK1 expression 2.68±0.12-fold ( P KAch to levels in cells from wild-type mice. Conclusions: These results support a unique molecular mechanism for insulin regulation of GIRK1 expression and parasympathetic response via SREBP-1, which might play a role in the pathogenesis of DAN in response to insulin deficiency in the diabetic heart.